Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw

Rinaldi, François; Denus, Simon de; Nguyen, Angela; Nattel, Stanley; Bussières, Jean-François

doi:10.1016/j.cjca.2016.08.010

Cited by 33 publications

(34 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…with 66 percent and 68 percent in 2018 and 2019, respectively ( N = 305/459 in 2018; N = 310/456 in 2019).Other characteristics of drugs in shortage during the pandemic are distributed similarly to previous years. Most reports concern older and generic medicines, consistent with previous analyses of drug shortages in Canada and elsewhere ( Drug Shortages Task Force 2019 ;Donelle et al 2018 ;Rinaldi et al 2017 ). The form and route distribution of the March-April 2020 shortages also do not differ substantially from previous years.…”

supporting

confidence: 78%

COVID-19’s Limited Impact on Drug Shortages in Canada

Gaudette

2020

Canadian Public Policy

View full text Add to dashboard Cite

Analysant les données du site Web Pénuries de médicaments Canada, l'auteur se demande si les premiers mois de la pandémie causée par le coronavirus 2019 (COVID-19) ont été associés à une hausse importante des pénuries de médicaments au Canada. La hausse qu'il observe dans le nombre de pénuries signalées par les fabricants au cours des mois de mars et avril 2020, par rapport aux mêmes mois des années précédentes, s'établit à 147 (soit 32 pour cent). Cette hausse est concentrée dans la période de deux semaines se situant entre le 25 mars et le 7 avril 2020, après quoi le nombre des pénuries signalées revient aux niveaux habituels. Cette disproportion des pénuries signalées est attribuable à des causes liées tant à l'offre qu'à la demande. Des hausses sont constatées dans les classes thérapeutiques associées aux soins exigés par la COVID-19. Mots clés : chaîne d'approvisionnement pharmaceutique, chocs de santé publique, demande pharmaceutique, pénuries de médicaments Using data from the Drug Shortages Canada website, we ask whether the fi rst months of the coronavirus disease 2019 (COVID-19) pandemic were associated with a signifi cant increase in drug shortages in Canada. We fi nd an increase of 147 shortages (32 percent) reported by manufacturers during March and April 2020 relative to the same months in previous years. The upsurge was concentrated during the two-week period from 25 March to 7 April 2020, after which report counts returned to usual levels. Excess reports cite both supply-side and demand-side causes for shortages. Increases were noted in therapeutic classes associated with COVID-19 care.

show abstract

supporting

confidence: 78%

COVID-19’s Limited Impact on Drug Shortages in Canada

Gaudette

2020

Canadian Public Policy

View full text Add to dashboard Cite

show abstract

“…Alongside the need to guarantee the supply of key medical and personal protective equipment to control the disease, there is a general concern regarding the preservation of the continued supply of medicines for all citizens. [3][4][5] Although no major disruptions in pharmaceutical access have been reported thus far, the existing issue of medicine shortages [6][7][8][9] may increase, due to the worldwide state of public health emergency. Expected constraints in the manufacturing process (e.g.…”

Section: Introductionmentioning

confidence: 99%

Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies

Romano

Galante

Figueira

et al. 2021

Research in Social and Administrative Pharmacy

View full text Add to dashboard Cite

Background: COVID-19 is a worldwide public health concern. Disruptions in the drug market are expected and shortages might worsen. Community pharmacies can contribute to early identification and report of medicines' supply and demand issues. Objective: The aim of this study is to characterize the impact of the COVID-19 outbreak on outpatient medicines' sales and shortages. Methods: A retrospective, time-trend analysis of medicine sales, shortages and laboratory-confirmed COVID-19 cases was performed from February 1st to April 30th, 2020, and its homologous period (regarding sales only). A detailed analysis of 6 pharmaceutical substances was performed. All data were subjected to rescaling using the min-max normalization method, in order to become comparable. Data analysis was performed using Microsoft® Excel. Results: The pandemic resulted in an increase in medicines' demand and reported shortages during the early stage of the outbreak. The maximum proportion of medicine sales was registered on March 13th, 2020, 4 days after the WHO declared COVID-19 a pandemic. By the end of March, sales have already dropped to proportions similar to those of 2019. The maximum proportion of drug shortages was reached about one week after the sales peak and by the end of the study period were below those recorded in the pre-COVID-19 period. The analyzed drugs were paracetamol, ascorbic acid, dapagliflozin plus metformin, rosuvastatin plus ezetimibe, formoterol, and hydroxychloroquine, as these pharmaceutical substances registered the highest growth rate in sales and shortages when compared to the same period in the previous year. Hydroxychloroquine showed the most different pattern trends on sales and shortages of these medicines. Conclusions: Pharmacies can provide timely and real-world data regarding sales and shortages. The adopted measures to guarantee the continuous supply of the medicine market seem to have worked. The long-term impacts of this pandemic are unknown and should continue to be closely monitored.

show abstract

“…Medicine shortages have a direct impact on patient outcomes through disrupting the continuity of patient care and potentially deteriorating treatment outcomes originating from timely scarcity of drug supply and substitution with a less safe and effective alternative and the potential for medication errors (Iyengar et al, 2016;De Weerdt et al, 2017;Rinaldi et al, 2017;France Assos Santé, 2018;Phuong et al, 2019). Consequently, risk management plays an important role in healthcare settings via minimizing the likelihood of identified risk-related consequences associated with drug shortages (The Australian Council on Healthcare Standards (ACHS), 2013; Iyengar et al, 2016;American Society of Health-System Pharmacists, 2018;Root, 2018).…”

Section: Introductionmentioning

confidence: 99%

Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications

et al. 2020

View full text Add to dashboard Cite

Results: The participants (61.7%) are aware of the use of risk assessment procedures as a coping strategy for medicine shortages, and named the particular risk assessment procedure they are familiar with failure mode and effect analysis (FMEA) (26.4%), root cause analysis (RCA) (23.5%), the healthcare FMEA (HFMEA) (14.7%), and the hazard analysis and critical control point (HACCP) (14.7%). Only 29.4% report risk assessment as integrated into mitigation strategy protocols. Risk assessment is typically conducted within multidisciplinary teams (35.3%). Whereas 14.7% participants were aware of legislation stipulating risk assessment implementation in shortages, 88.2% claimed not to have reported their findings to their respective official institutions. 85.3% consider risk assessment a useful mitigation strategy. Conclusion: The study indicates a lack of systematically organized tools used to prospectively analyze clinical as well as operationalized risk stemming from medicine shortages in healthcare. There is also a lack of legal instruments and sufficient data confirming the necessity and usefulness of risk assessment in mitigating medicine shortages in Europe.

show abstract

Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw

Cited by 33 publications

References 2 publications

COVID-19’s Limited Impact on Drug Shortages in Canada

COVID-19’s Limited Impact on Drug Shortages in Canada

Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies

Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications

Contact Info

Product

Resources

About